ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
1. ZyVersa's IC 100 targets inflammasomes to treat T2DM and cardiovascular issues. 2. Preclinical data show IC 100 reduces insulin resistance and inflammation. 3. The global burden of T2DM highlights urgent need for effective therapies. 4. ZyVersa plans Q4-2025 preclinical study for IC 100 with results by Q1-2026. 5. Inhibition of multiple inflammasomes could enhance IC 100's effectiveness.